SPIMA Therapeutics
Created in 2024
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
310Activities
Technologies
Entity types
Location
80 Av. Augustin Fliche, 34000 Montpellier, France
Montpellier
France
Employees
Scale: 2-10
Estimated: 3
Engaged corporates
1
1 1Added in Motherbase
1 month ago
deeptech Value proposition
Unlocking New Immunotherapy Paths with Smart Peptides
SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology.
SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most.
SPIMA Therapeutics is part of the nexus of Landmark Bioventures.
Join us in shaping the future of medicine, where discovery meets dedication.
ImmunotheryOriginal language
Unlocking New Immunotherapy Paths with Smart Peptides
SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology.
SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most.
SPIMA Therapeutics is part of the nexus of Landmark Bioventures.
Join us in shaping the future of medicine, where discovery meets dedication.
Spima Therapeutics
Unlocking New Paths with Smart Peptides
https://www.spima-therapeutics.com/
